Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169219 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT02169219: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02169219 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02169219, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating ANCA-associated vasculitis.
Interventions
- DRUG Rituximab
- DRUG Glucocorticoids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169219
The ClinicalTrials.gov registry entry for NCT02169219 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02169219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169219 about?
NCT02169219 is a clinical study titled "Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis". The purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating ANCA-associated vasculitis.
What is the current status of trial NCT02169219?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2014-06. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT02169219?
The interventions under investigation include: Rituximab (DRUG), Glucocorticoids (DRUG).
Who is sponsoring clinical trial NCT02169219?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.